Dublin-based Alkermes has seen sales of its opioid abuse drug Vivitrol soar in recent years as communities have scrambled for ways to fight opioid addiction and the overdoses that come with it.
Now the drugmaker intends to increase capacity of the drug’s production and add nearly 100 jobs to the Ohio plant that manufactures it.
The expansion will add about $5.3 million in payroll, along with the 90 added jobs, to the Wilmington, Ohio, plant, according to the Ohio Tax Credit Authority, reported the Dayton Business Journal. The authority has granted tax benefits for the project. The drugmaker has also agreed to maintain about 400 already working at the 280,000 square plant. A spokesperson could not be reached Monday.
Vivitrol is manufactured exclusively at the Wilmington plant. Approved 10 years ago, it had little success as a treatment for alcoholism but after being approved to treat opioid abuse, sales of the $1,300-a-month drug have grown significantly, up 53% last year to $144.4 million. The company has yet to report its Q4 or 2016 full-year’s numbers, but in Q3, the company reported net sales of Vivitrol reached $55.8 million, up 47% from sales of $37.9 million in the same quarter of 2015.
Vivitrol is among drugs decided to keep when it made the decision in 2015 to narrow its focus. At the time, it sold a half dozen drugs and a manufacturing plant in Gainesville, Georgia, to Pennsylvania-based Recro Pharma. Recro agreed to pay $50 million in cash and up to $120 million in milestone payments.
By Eric Palmer
Source: Fierce Pharma
CordenPharma announced its largest strategic investment to date, committing to spend ~€900m over the next three years to enhance its peptide technology platform. The planned investment consists of two major expansion initiatives occurring in parallel in the US and Europe, including both existing facilities and new constructions.
DSM-Firmenich has announced the sale of its MEG-3 fish oil business to KD Pharma Group, a contract development and manufacturing organisation that is active in pharmaceutical and nutritional lipids. As part of the transaction, DSM-Firmenich will obtain a minority stake of 29% in KD Pharma’s parent company O³ Holding GmbH.
Veranova, a development and manufacturing of specialist and complex APIs for the pharmaceutica l and biotech sectors, recently announced the appointment of Cécile Maupas as Senior Vice President, Chief Commercial Officer. Cécile will join the executive team and assume responsibility for business development, marketing, project management, commercial operations, and product management.
